home

clinical

presbyopia

Clinical

Articles

An increase in popularity of the use of handheld electronics is resulting in changes in the postural and behavioral patterns of device users, as well as significant differences between presbyopes and non-presbyopes and between genders.  

Gender, visual status determine differences in viewing distances of smartphones 

Researchers report “very good results" in assessing the visual results and patients satisfaction in a series of patients following following implantation of the AcrySof PanOptix trifocal IOL (Alcon). 

PanOptix trifocal lens: good results, high satisfaction in presbyopic patients

Veteran optometrist has seen them all and is waiting for the next innovation

The many options of vision correction

Poll results: What pipeline presbyopia treatment are you most looking forward to?

Dr. Chang is a subinvestigator in numerous clinical trials. He is immediate past president of New Jersey Academy of Optometry, and an advisory board member for International Keratoconus Academy for Eye Care Professionals (IKA), Gas Permeable Lens Institut

Sheryl brings a wealth of editorial experience to MJH Life Sciences’ Eye Care Network, having engaged with the readers and the greater ophthalmic community of 

for more than 20 years. As Group Editorial Director, Sheryl’s purview extends across the print and digital network of 

Ophthalmology Times, Ophthalmology Times Europe, Modern Retina 

 Prior to ophthalmology, Sheryl previously covered the fields of audiology and confectionery science/technology/manufacturing.

Sheryl is also passionate about the mission, vision and values of Ophthalmic World Leaders (OWL) and recently completed her term on its Board of Directors. She continues to volunteer as Editor-in-Chief of the organization’s 

Magazine. In 2013, she was honored with the group’s inaugural Rising Star Award.

In addition, she has served as a judge for 

 Health Care Heroes Awards program as well as the Jesse H. Neal National Business Journalism Awards.

Videos

As the number of presbyopia patients continues to grow, so do their visual demands.

The next frontier of presbyopia treatments

VUITY, developed by Allergan, is the first and only FDA-approved eye drop to treat presbyopia

Eye drops for presbyopia treatment receive FDA approval

Poll

This poll is for optometrists and eyecare professionals, only. It will close on Friday, November 5, 2021.

Poll: What pipeline presbyopia treatment are you most looking forward to?

Innovative treatment options reflect a shift in focus

Pupil size matters in presbyopia treatment

Poll results: What is your first-line approach to emergent presbyopes who wear contact lenses?

Orasis Pharmaceuticals drop in development for treating presbyopia

Presbyopia